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1. Introduction 
This chapter deals with recent advances in the nanovector approach to the pulmonary 
delivery of therapeutic substances; it also describes briefly the physiology of the lungs and 
the main factors affecting pulmonary delivery (Figure 1). 
The development of an innovative nanocarrier, able to deliver the drug to the desired site of 
action, is highly dependent on the nature of the active substance and on its desired mode of 
action.  
A delivery technology can thus be used to: 
 reduce systemic exposure and improve drug targeting; 
 circumvent the parenteral route or  reduce the number of injections; 
 achieve sustained plasma levels of the drug; 
 reduce side – effects; 
 modulate the effect of the drug, specifically in the case of vaccines, where the delivery 
system can modify the ratio of humoral and cellular response; 
 increase patient compliance; 
  reduce the price of the therapy; 
 increase patent life and/or circumvent patents of competitors. 
Numerous approaches involving non - parenteral routes, such as intestinal, nasal, buccal, 
transdermal and rectal, have been examined, but most of them are inadequate for a 
satisfactory therapeutic response. On the other hand, the pulmonary route represents a great 
promise for the systemic delivery and bioavailability of peptides and proteins, since lungs 
are highly permeable and accessible by normal inhalation methods. Actually, the pulmonary  
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Fig. 1. Factors affecting pulmonary delivery 
route typically shows from 10 to 200 times greater bioavailability with respect to other non - 
invasive routes (Patton & Byron, 2007 ). Thus, various pharmaceutical techniques have been 
introduced to take advantage of this route. These include formulations using specific and 
innovative excipients, chemical modifications of drugs, polymeric and/or amphiphilic Drug 
Delivery Systems (DDSs), particle engineering, inhalation devices. 
In particular, over the past decade, the use of DDSs involving micro or nanocarriers and 
particle engineering techniques were remarkably developed and the resulting 
pharmaceutical techniques have been eagerly applied to the pulmonary delivery of drugs.  
Inhalation is also a proven means of systemic delivery for drugs that have limited 
bioavailability by other routes or would benefit from rapid onset of action and a variety of 
products are being developed for this purpose (Gonda, 2006; Patton & Byron, 2007 ).  
At the same time, in recent decades, advances in device design and formulation science have 
addressed the need for more efficient inhalers that are capable of delivering larger doses to 
the lung with low extrathoracic deposition. Once deposited in the lungs, drug disposition 
(dissolution, absorption, distribution, metabolism and elimination) and the influence of 
pulmonary pharmacokinetics (PK) are the critical determinants of clinical outcomes in terms 
of drug efficacy and safety. Pulmonary disposition remains poorly understood despite 
modern capabilities in imaging, analytical and biological science which make measurement 
of drug disposition and mode of action more accessible. For these reasons the development 
of new inhaled medicines capable to allow improvements in current therapy is a promising 
challenge in the  development new DDSs. 
A number of benefits result from inhalation of drugs and a continuously increasing number 
of inhaled drugs and nanomedicines are becoming available for the treatment various 
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diseases. Inhalation of drugs is convenient and extremely efficient to treat diseased airways. 
It allows a targeted therapy with high drug concentrations in the tissue of interest and low 
systemic drug exposure (and thereby reduced side effects). Inhalation aerosols have also 
been developed for systemic drug administration. The large absorptive surface area, the 
very thin diffusion path to the bloodstream and the elevated blood flow make the lung a 
port of entry to the systemic circulation and proteins are absorbed more efficiently from the 
lungs than from any other non-invasive route of drug administration. 
Only one inhaled therapeutic protein is currently available on the market. It is recombinant 
human deoxyribonuclease I (Dornase alfa) indicated for the treatment of cystic fibrosis (CF) 
and marketed since 1994. 
Recombinant human deoxyribonuclease I is a glycoprotein of 37 kDa, which selectively 
cleaves DNA. In CF patients, retention of viscous purulent secretions in the airways 
contributes both to reduced pulmonary function and to exacerbation of infection. Purulent 
pulmonary secretions contain very high concentrations of extracellular DNA released by 
degenerating leukocytes. Dornase alfa is delivered to CF patients by inhalation of an aerosol 
mist produced by a pneumatic nebulizer. It hydrolyses the DNA in airway secretions and 
reduces their viscoelasticity. 
Inhalation can represent the most favourable non-invasive route of administration for 
insulin (5.8 kDa) because insulin bioavailability can reach 37% following inhalation while it 
reaches at most 1% following oral, sublingual, nasal or transdermal administration without 
chemical enhancers (Cefalu, 2004; Illum, 2002). The first inhaled insulin product, Exubera®, 
was approved in January 2006 but withdrawn from the market already in October 2007 due 
to disappointing sales. 
Another inhaled insulin product, AFREZZA™, is currently under review by the FDA for the 
treatment of type 1 and type 2 diabetes (Neumiller & Campbell 2010; Rossiter et al., 2010). 
AFREZZA™ is an ultra rapid acting insulin comprising Technosphere® insulin powder in 
unit dose cartridges for administration with the inhaler. The Technosphere® powder 
formulation is prepared by precipitating insulin from solution onto preformed 
diketopiperazine particles, which readily dissolve once in the lung environment. 
AFREZZA™ appears to overcome several limitations of Exubera®. Technosphere® insulin 
is both rapidly absorbed and eliminated and its pharmacokinetic profile mimics more 
closely normal physiologic insulin release than injection of regular human insulin as well as 
of rapid-acting analogues. 
A few small-scale clinical trials have been conducted on inhalation of other systemically-
acting therapeutic proteins, including interferon alpha-2b (19.3 kDa), human growth 
hormone (22 kDa) (Walvoord et al., 2009), an erythropoietin-Fc fusion protein (112 kDa) 
(Dumont et al., 2005). Inhalation of growth hormone is a potential alternative to growth 
hormone injection, which could offer improved patient adherence especially in pediatric 
patients. The bioavailability of inhaled growth hormone was 3.5% relative to subcutaneous 
injection in children, while it reached 7.6% in adults (Walvoord et al., 2009). The hypothesis 
behind this difference is that children have smaller oropharynx and larynx, which results in 
different deposition patterns as compared to adults. Although children preferred the 
inhalation route of therapy, ongoing development of growth hormone inhalation has been 
delayed due to its low bioavailability. An erythropoietin-Fc fusion protein was absorbed in 
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the bloodstream following delivery to the central lung regions in humans, with a dose-
dependent concentrations in the serum, suggesting that large therapeutic molecules can be 
delivered to humans via the lungs using the FcRn-mediated transport pathway (Dumont et 
al., 2005). 
2. Practical issues in the pulmonary delivery 
2.1 Physiological features of the lungs 
The lung resembles an inverted tree, where the trachea or trunk subdivides into two main 
bronchi and these latter successively branch into more and more narrow and short 
bronchioles. In total, the trachea undergoes 23 bifurcations before it reaches the alveolar 
sacs. The first 16 generations compose the conducting region where air is filtered, warmed, 
humidified and conducted to the respiratory region. Gas exchange between airspaces and 
blood capillaries occurs in the respiratory region, which includes the respiratory 
bronchioles, the alveolar ducts and the alveolar sacs. 
Two different epithelia line the conducting and respiratory regions. A pseudo stratified 
columnar epithelium lines the proximal conducting airways and is composed of ciliated 
columnar cells, goblet or mucus secreting cells and basal or progenitor cells (Parkes, 1994). It 
is progressively replaced by a simple cuboidal cell layer in the more distal airways and by a 
very thin epithelial lining in the alveoli. Squamous type I pneumocytes cover 95% of the 
alveolar surface, owing to their large apical surface and thinness (0.05 μm). Cuboidal type II 
pneumocytes produce the lung surfactant and are progenitor for type I cells. Type II 
pneumocytes are located in the corners of the alveoli. The surface area of the alveolar 
epithelium reaches 100 m2, which is enormous as compared to the 0.25m2 surface area of the 
airways (Crapo et al.,1982;  Mercer et al., 1994). 
Mucociliary clearance is one of the most important defense mechanisms to eliminate dust 
and microorganisms in the lungs (Van der Schans, 2007). 
The mucus is produced by goblet cells and sub-mucosa glands. It covers the entire airway 
surface and its thickness ranges from 5 μm to 55 μm (Clunes & Boucher, 2007; Lai et al., 
2009). It consists of an upper gel phase made of 95% water, 2% mucin, a highly glycosylated 
and entangled polymer, as well as salts, proteins and lipids (Bansil  & Turner, 2006). A 
periciliary liquid layer underlies the mucus gel and its low viscosity allows effective cilia 
beating. The mucus is transported by the coordinated beating of the cilia and by expiratory 
airflow towards the oropharynx at an average flow rate of 5 mm per minute. Mucus, cells 
and debris coming from the nasal cavities and from the lung meet in the pharynx, are mixed 
with saliva and are swallowed. 
Pulmonary surfactant is responsible for biophysical stabilizing activities and innate defense 
mechanisms. It lines the alveolar epithelial surfaces and overflows into the conductive 
airways so that the surfactant film is continuous between alveoli and central airways 
(Bernhard et al., 2004). Pulmonary surfactant is composed of 80% phospholipids (half of 
which being  dipalmitoylphosphatidylcholine), 5–10% neutral lipids (mainly cholesterol), 5–
6% specific surfactant proteins and 3–4% non-specific proteins (Perez-Gil, 2008).  
The phospholipids are mainly responsible for forming the surface active film at the 
respiratory air–liquid interface. In water, phospholipids self-organize in the form of bilayers. 
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Bilayers are also the structural form in which surfactant is assembled and stored by 
pneumocytes in lamellar bodies. At the air–liquid interface, phospholipids form oriented 
monolayers, with the hydrophilic headgroups oriented towards the aqueous phase and the 
hydrophobic acyl chains pointing towards the air. The higher the concentration of 
phopholipid molecules at the interface, the lower the surface tension, the lower the energy 
required to enlarge the alveolar surface during inspiration. 
Specific surfactant proteins include SP-A, SP-B, SP-C and SP-D. SP-A and SP-D are 
hydrophilic while SP-B and SP-C are hydrophobic. SP-A is able to bind multiple ligands, 
including sugars, Ca2+ and phospholipids. This property allows SP-A to bind to the surface 
of pathogens, contributing to their elimination from the airways. Recognition of SP-A by 
specific receptors on alveolar macrophages stimulates phagocytosis of the pathogens. SP-B 
is strictly required for the biogenesis of pulmonary surfactant and its packing into lamellar 
bodies. Both, SP-B and SP-C promote rapid transfer of phospholipids from bilayers stores 
into air– liquid interfaces. 
Luminal airway and alveolar macrophages are at the forefront of lung defence and their 
primary role is to participate in innate immune responses, that is, chemotaxis, phagocytosis, 
and microbial killing  (Geiser, 2010). They also downregulate adaptive immune responses 
and protect the lung from T-cell-mediated inflammation (Holt  et al., 2008). Macrophages 
are tightly applied on the surface of respiratory epithelia. They are immersed in the lung 
lining fluid beneath the surfactant film. 
Although they occupy only 1% of the alveolar surface, they are capable to clean particles 
from the entire alveolar surface due to amoeboid movements (Geiser, 2010). In contrast to 
surface macrophages, interstitial macrophages are primarily involved in adaptive immunity 
by interfacing with lymphocytes via antigen presentation and production of cytokines 
(Geiser, 2010). 
The lung presents a lower level of metabolism than the gastrointestinal tract and liver. Yet, 
various peptidases are distributed on the surface of different cell types in the lung, including 
bronchial and alveolar epithelial cells, submucosal glands, smooth muscles, endothelial 
cells, connective tissue. Proteases are largely present in lysosomes (Buhling et al., 2004). 
Proteases that degrade the extracellular matrix are secreted by different structural cells or 
are membrane bound (Stamenkovic, 2003). 
Proteases play an essential role in cell and tissue growth, differentiation, repair, 
remodelling, cell migration and peptide-mediated inflammation (van der Velden & 
Hulsmann, 1999). Proteases can also be released in the airspaces by activated macrophages 
and neutrophils in case of inflammatory reactions in the respiratory tract (Buhling et al., 
2006; Tetley, 2002). Blood supply to the lungs is divided among the pulmonary and systemic 
circulations (Altiere & Thompson, 1996). The pulmonary circulation consists of the 
pulmonary artery that leaves the right heart, branches into a dense pulmonary capillary bed 
that surrounds the alveoli and finally coalesces into the pulmonary vein that drains into the 
left heart. One hundred percent of the cardiac output flows through the pulmonary 
circulation. Its principal functions are gas exchange with air in the alveoli and nutrients 
supply to terminal respiratory units. The lungs receive a second blood supply via the 
systemic circulation, commonly referred to as the bronchial circulation. The bronchial 
circulation originates from the aorta and provides oxygenated blood and nutrients to all 
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structures of the tracheobronchial tree. Lymphatic vessels exist in close proximity of major 
blood vessels and of the airways (El-Chemaly et al., 2009). The lungs have unique 
physiological features and provide many conditions that favour the absorption of peptides 
and proteins.  
2.2 Barriers to the pulmonary delivery of active substances 
2.2.1 Deposition of nanocarriers through the respiratory tract 
As pointed out in the section on lung physiology, the structure of the lung tissue largely 
varies according to airway generation and the fate of nanomedicines will similarly vary 
depending on the structures on which they deposit. The site of deposition of an inhaled 
formulation within the respiratory tract depends on the aerodynamic diameter of the 
aerosol particles. The aerodynamic diameter of a particle, daer, is equivalent to the diameter 
of a unit density (ρ0) sphere that has the same terminal velocity in still air as the particle: 
  
(1)
 
where d is the geometric diameter of the particle, ρ is the particle density and χ is the 
particle dynamic shape factor  denoting deviation of shape from sphericity (Hinds, 1999). 
Filtering of large particles (daer >5 μm) occurs in upper airways (mouth, trachea and main 
bronchi) by inertial impaction. One to 5 μm daer particles deposit by gravitational settling in 
the central and distal tract. Particles with daer <1 μm remain suspended in the air and are 
mostly exhaled. Ultrafine particles (<100 nm) can largely deposit in the respiratory tract by 
random Brownian motion: particles <100 nm reach the alveolar region while particles <10 
nm already deposit in the tracheo-bronchial region due to their high diffusion coefficients 
(Heyder at al., 1986). 
Drug delivery inhalers, that include nebulizers, metered-dose inhalers and dry powder 
inhalers, generate particles with a daer in the micron-size range for deposition in the tracheo-
bronchial tree (3–10 μm) in order to treat the airways (e.g., β2 mimetics) or in the alveolar 
region (1–3 μm) for systemic drug absorption (e.g., insulin) (Figure 2).  
Therapeutic proteins can be delivered to the lungs by any medical inhaler. Yet, medical 
inhalers are not designed to produce ultrafine particles. Ultrafines require enormous energy 
for their creation, that is, for the atomization of the solution into nano-sized liquid droplets 
or for the complete de-agglomeration of nanosized dry powder particles. Therefore, drug 
formulations based on nanoparticles are most often delivered to the respiratory tract by 
nebulization of colloidal suspensions (Dailey et al., 2003). Developments of the preparation 
of dry powder microparticles as nanoparticles carriers for pulmonary drug delivery were 
also reported quite recently (Tsapis et al., 2002). It should be noted, ultrafines are generated 
in abundance in our environment by the most significant pollution sources, which are those 
related to combustion processes (Morawska et al., 2005). Epidemiologic studies have 
provided evidence that an increase in atmospheric ultrafines is associated with adverse 
pulmonary and cardiovascular effects in susceptible parts of the population. Therefore, 
significant research has focused on the fate of inhaled ultrafines in the body and ultrafines 
have been frequently produced in laboratories using spark generators (Geiser et al., 2008).  
X
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Fig. 2. Deposition of nanocarriers in human respiratory tract as a function of size 
Data from several of these studies have been included in this review as the pulmonary fate 
of atmospheric ultrafines has likely similarities with the pulmonary fate of nanomedicines 
(Geiser et al., 2008; Furuyama et al., 2009). 
2.2.2 Clearance mechanisms 
Various elimination pathways for nanoparticles exist in the lungs, including coughing, 
dissolution, mucociliarly escalator, translocation from the airways to other sites, 
phagocytosis by macrophages and neuronal uptake (Figure 3); but the quantitative 
relationship among these pathways has not yet been established (Muhlfeld et al., 2008).  
 
Fig. 3. Pathways involved in nanocarriers absorption 
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When a nanoparticle has landed on the airways, it first encounters the surfactant on the top 
of the airway lining fluid. The surfactant will enhance particle wetting thus helping it to sink 
into the fluid, passing first through the gel phase and then to the sol phase. Compared with 
sulphur colloidal particles (220 nm), human serum albumin molecules (HSA, 66 kDa) were 
cleared 3 times more slowly from the bronchi of dogs. This difference was attributed to the 
possibility that sulphur nanoparticles resided on the gel phase (i.e. the top layer of the 
periciliary fluid) whereas HSA dissolved and partitioned into the sol (i.e. bottom layer) 
which may be transported less effectively by mucociliary clearance (MCC). If extrapolated to 
inhaled drugs, the more soluble ones will behave like HSA and should be hence less 
susceptible to MCC (Edsbacker et al., 2008), but more likely absorbed through the 
epithelium. For nanoparticle agglomerates, it is likely that the particles will first reside on 
the gel phase. Depending on the aqueous dispersibility and solubility in the airway fluid, 
the agglomerates may remain in the gel phase behaving like the microsized particles, or they 
may then disperse into nanoparticles followed by dissolution and absorption. Nanoparticles 
delivered within a liquid droplet (e.g. from a nebulizer) might be different from dry 
particles, as the droplet liquid may interact with the gel layer making the nanoparticles 
easier to wet and partition into the sol layer, i.e. potentially more readily to escape the MCC 
(Zhang et al., 2011). 
2.2.2.1 Dissolution 
Dissolution depends on the site of deposition, which determines the volume of airway fluids 
available for dissolution and, hence, whether the dissolution occurs in sink or non-sink 
conditions, as well as on the solubility and dose of the drugs. Freely water soluble drugs 
include organic salts (e.g., salbutamol sulphate, terbutaline sulphate and disodium 
cromoglycate) and polar compounds (e.g. mannitol). These drugs will dissolve readily in the 
airway fluid followed by absorption or elimination by the mucociliarly escalator. Sparingly 
soluble drugs include the inhaled corticosteroids, which have aqueous solubility ranging 
from 140 to below 0.1 μg/mL (Edsbacker et al., 2008). Once dissolved, the drug molecules 
are diluted in the airway fluid where they can bind to proteins, opsonins, or other 
constituents and be metabolized and/or absorbed into the blood and lymph ( Schmid et al., 
2010). 
Absorption of the drugs depends on the site such as alveolar or conducting airways (which 
affects the barrier thickness and surface area) and the drug molecule itself (which impacts 
on passive diffusion and active uptake by the epithelium. It must be pointed out that 
absorption of most drugs from the lungs is rapid: as an example, it has been reported that 
following inhalation of formoterol fumarate (4.5 nmol/L) and budesonide (136 pmol/L, the 
peak plasma concentrations  occurred at 20 and 10 min, respectively. 
2.2.2.2 Mucociliary clearance (MCC) 
MCC operates in the ciliated airways where the movement of the cilia transports the mucus 
carrying the drug nanoparticles or dissolved drug (not yet absorbed) on the epithelial 
surface towards the pharynx/larynx. The drug-containing mucus will then be swallowed to 
the GI tract. The average transport velocity in the human trachea has been estimated at 3–10 
mm/min, but the value varies widely among subjects. Using well-developed techniques of 
depositing radiolabelled sulfur colloids in the central airways, Daviskas and her colleagues 
reported a MCC rate remarkably reduced in patients with bronchiectasis, asthma, and CF, 
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with respect to healthy individuals. Actually, MCC and dissolution occur simultaneously 
and their relative importance should depend on the elimination rate from each of these 
contributions. While insoluble particles of 6 μm are practically all cleared from the bronchial 
airways by MCC in 24 h, smaller particles are retained for a longer period showing almost 
an inverse relationship between the 24 h airway retention and the geometric particle size. 
Nanoparticles with enhanced mobility may partition through the mucus into the periciliary 
spaces, where they can be taken up by the airway macrophages and bronchial epithelial 
cells, causing a reduction of MCC (Schmid et al., 2009). 
2.2.2.3 Macrophage uptake 
Alveolar macrophages are responsible for clearance of nanoparticles deposited in the 
alveolar region, in which MCC is absent. In response to the deposited nanoparticles, 
alveolar macrophages will migrate to the particles and phagocytize them via chemotaxis 
involving opsonisation. Macrophage uptake is believed to complete within 6–12 h after 
deposition of the particles in the alveoli (Oberdörster, 2007). nce internalized in the 
macrophages, the particles will be either disintegrated (e.g. by enzymes in lysosomes) or 
accumulated in the lymphatic system (Schmid et al., 2009) draining both airways and 
alveoli and finally terminating in the mediastinal and hilar lymph nodes (Geiser & 
Kreyling, 2010). A minor fraction of the particle-carrying macrophages will migrate to the 
ciliated airways where they are removed by MCC (Schmid et al., 2009). However, with a 
retention half-time of up to 700 days in humans (Oberdörster, 2007), clearance of solid 
particles by alveolar macrophages is a relatively slow mechanism. Phagocytosis of 
particles below 100 nm is not effective (Oberdörster, 2007), most probably because of a 
less effective recognition (~20%) of nanoparticles by the macrophages (Schmid et al., 
2009). The reduced recognition is possibly due to more scattered and diluted chemotactic 
signals as a result of i) higher number concentration of nanoparticles (compared with 
micron-sized particles at the same dose) and ii) fewer opsonin molecules available per 
particle. Conversely, since nanoparticles are more readily taken up by epithelial cells, they 
become less available to be phagocytized by macrophages (Madl & Pinkerton, 2009). 
Macrophages are also present in the ciliated airway  but their role in nanoparticle 
clearance is  probably less important compared with MCC.  
2.2.2.4 Translocation into cells, blood and lymph 
This process involves transcytosis of the particles into the epithelial cells and/or across the 
epithelia of the respiratory tract into the interstitium and then to blood and lymph. As 
described earlier, translocation to the lymphatic system can be facilitated by macrophage 
uptake. The transport may be protein-mediated, requiring binding of certain proteins on the 
nanoparticle surface for recognition by the receptors (Schmid et al., 2009). The transport may 
also be receptor-mediated transcytosis via caveolae (Oberdörster, 2007), which have a 
diameter of 50–100 nm. Surface coating of the particles by albumin and lecithin may 
facilitate cellular uptake by pneumocytes and transcytosis across capillaries (Yang et al., 
2008). Once internalized, nanoparticles can bind to mitochondria and even DNA in the 
nucleus (Muhlfeld et al., 2008; Oberdörster, 2007). 
When translocated to the systemic circlulation, nanoparticles could cause unwanted effects 
on the blood (e.g. accumulation in platelets) and other organs in the body (Oberdörster, 
2007). Some biological effects may include inflammation, oxidative stress, cytotoxicity, 
fibrosis, and immunologic responses ( Madl & Pinkerton, 2009; Unfried et al., 2007). 
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Surface area has been proposed as the single most important particle dose parameter for the 
toxicity of nanoparticles (Schmid et al., 2009). This is particularly relevant for inflammatory 
and oxidative stress reactions, such as surface area of a catalyst (i.e. nanoparticles), that 
determines the oxidative reaction rate. However, oxidative stress involves the formation of 
reactive oxygen species (ROS) from the particles containing reactants such as transition 
metals or polyaromatic hydrocarbons (which induce the expression of the CYP1A1 protein). 
Drug nanoparticles, which do not contain such reactants, are therefore less likely to cause 
oxidative stress in the lungs. Biodegradabile nanoparticles indeed showed significantly 
lower inflammatory response in-vitro (Sung et al., 2007). Interestingly, translocation in the 
reverse direction with particles re-entrained from the lung capillaries or interstitium to the 
luminal side of the epithelium have been shown in animal models using rabbits and rats. 
Such back-translocation was suggested to be macrophage-mediated.  
2.2.2.5 Neuronal uptake 
Translocation into afferent vagal nerves in the tracheobronchial airways has been proposed 
but still not well studied (Oberdorster et al., 2005). Nanoparticles deposited in the nasal 
cavity have been reported to be taken up by the olfactory lobe and translocated to the 
central nervous system (Oberdorster et al., 2005). However, such a neuronal uptake 
pathway is relevant only if the drug nanoparticles are inhaled nasally. Existing data from 
epidemiologic and toxicological studies showed longer retention of inhaled nanoparticles in 
the lungs, but the applicability of these findings on nanoparticles is under investigation. In 
theory, inhaled nanodrug particles have the potential to be retained longer in the lungs 
followed by cellular uptake and translocation into the systemic circulation thus causing 
nanotoxicity. It can be speculated that the fate of the nanoparticles in the lungs, regarding 
the elimination pathways, will depend on the properties of both the particle and the drug 
molecule. Micron-sized aggregates of nanoparticles will deposit by sedimentation in the 
tracheobronchial (TB) region where MCC will operate to eliminate both the dissolved and 
undissolved drugs. Even discrete nanoparticles can deposit by diffusion in the TB region. 
Drug nanoparticles deposited in the alveolar region will dissolve in the airway fluid and be 
absorbed. This is likely to be the case even for hydrophobic drugs with low aqueous 
solubility like inhaled corticosteroids due to the relatively low doses that are used. As a 
result of the low persistence of drug nanoparticles, dissolution and mucociliary escalator 
will likely be the major clearance pathways responsible for these particles before 
macrophage phagocytosis and other translocation pathways would start to play a significant 
role. 
3. Nanocarriers for lung delivery 
Nanomedicine can be defined as the application of nanotechnology to medicine. 
Nanotechnology involves the understanding and control of matter at dimensions of 1 to 100-
200 nm, where unique phenomena enable novel applications. Artificial nanostructures are of 
the same size as biological entities and can readily interact with biomolecules on both the 
cell surface and within the cell (Figure 4). Here our attention is focused on the fate of 
nanomedicines delivered to the lung, in particular an innovative glucocorticoid delivery 
system will be considered. 
The understanding the fate of nanomedicines in the lungs is important because fate and 
therapeutic activity are closely related. Interaction of nanomedicines with cells of the  
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Fig. 4. Nanocarrier size  
respiratory system will determine the pharmacodynamic response. For instance, the rapid 
uptake of particles by alveolar macrophages can be a way of targeting anti-tuberculosis 
drugs to this type of cells (Nimje et al., 2009). Conversely, macrophages uptake represents a 
clearance pathway for drugs acting on other cells within the lungs (e.g., β2 mimetics). 
Nowadays, biopharmaceuticals and conventional drugs are frequently engineered or 
incorporated in carriers in order to direct their fate in preferential pathways (Schmidt, 2009; 
Veronese & Pasut, 2005). Nano-size drug carriers can incorporate various therapeutics 
(e.g.,poorly water soluble drugs) and present several advantages for drug delivery to the 
lung including controlled release, protection from metabolism and degradation, decreased 
drug toxicity and targeting capabilities. Moreover, the successful integration of novel drugs 
with devices capable of delivering defined doses to the respiratory tract has resulted in a 
proven track record for inhalation as a route of administration that limits systemic exposure 
and provides localized topical delivery. Thus, a number of orally inhaled products have 
been successfully developed over the last 50 years, providing symptomatic relief to millions 
of patients with asthma and chronic obstructive pulmonary disease (COPD). 
There are numerous types of nanoparticle systems now being explored for drug delivery to 
lungs, especially in cancer treatment (Haley & Frenkel, 2008). 
The types of nanoparticle used at present in research for cancer therapeutic applications 
include polymeric nanoparticles, protein nanoparticles, ceramic nanoparticles, viral 
nanoparticles and metallic nanoparticles (Balak et al., 2010). 
Liposomes are the most extensively investigated system for controlled drug delivery to the 
lungs (Mansour et al., 2009). A few liposome-encapsulated antibiotics have been delivered 
to the lungs in phase II clinical trials. These include amikacin (Weers et al., 2009) and 
ciprofloxacin (Bruinenberg et al., 2010) Multiple treatment cycles with ARIKACE™ 
(liposomal amikacin for inhalation) showed sustained improvement in lung function with 
significant reduction in bacterial density in CF patients who have chronic Pseudomonas 
lung infections (Okusanya et al., 2009). 
A nanoscale liposomal formulation of amikacin has been shown to slowly release the drug in 
rat lungs and to penetrate Pseudomonas biofilms and CF sputum in vitro (Meers et al., 2008). 
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Mitsopoulos and  Suntres reported that the delivery of N-acetylcysteine as a liposomal 
formulation improves its effectiveness in counteracting Paraquat-induced cytotoxicity 
(Mitsopoulos &  Suntres, 2011). 
Liposomal drug dry powder formulations, realized to obtain novel devices capable of 
delivering defined doses of drugs, represent promising tools for pulmonary drug 
administration, such as selective localization of drug, reduced local and systemic toxicities, 
increased patient compliance and high dose loading. 
In liposomal dry powder formulations, drug encapsulating liposomes are homogenized, 
dispersed into the carrier and converted into dry powder by using freeze drying, spray 
drying or supercritical fluid technologies.  
The most commonly used liposomes are composed of lung surfactants and synthetic lipids. 
Liposomal formulation have been proposed to delivery  anticancer drugs, corticosteroids, 
immunosuppressants, antimicotic drugs, antibiotics for local pulmonary infections and CF 
and opioid analgesics for pain management using. Many of them have reached the stage of 
clinical trials for the treatment of several pulmonary diseases (Misra et al., 2009).  
A promising application of nanocarriers to lung targeting is related to gene delivery. Gene 
therapy is currently being developed for a wide range of acute and chronic lung diseases, 
incuding CF, cancer and asthma (Griesenbach & Alton, 2009; Lam et al., 2011). Nguyen et al 
(2009) developed a highly efficient nanocomposite aerosol for pulmonary gene delivery, 
consisting of a biodegradable polymer core. 
Respiratory diseases have attracted particular attention as targets of siRNA - mediated 
therapeutics, due to the lethality and prevalence of certain illnesses and the lung’s 
accessibility to therapeutic agents via both local and systemic delivery routes. However, one 
of the major challenges to realize the RNAi therapeutic potential in lung diseases is to 
deliver the siRNAs to the lung tissue, in particular, to the target cells with high efficiency 
and high specificity (Yuan et al., 2011).  
Several clinical trials have been conducted in order to assess the efficacy and safety of 
pulmonary DNA delivery using viral and non-viral vectors, especially in the case of CF. Yet, 
none of these formulations have been pursued due to low transfection efficiency, transient 
gene expression or immune elimination of the gene vector. Identifying the barriers to cell 
transfection might help to improve gene transfer efficiency of non-viral vectors (Griesenbach 
& Alton, 2009). An efficient and safe cationic lipid, 6-lauroxyhexyl lysinate (LHLN), was 
proposed to prepare cationic liposomes. In vitro tests showed that, compared with 
Lipofectamine2000, the new cationic liposome formulation using LHLN exhibited lower 
cytotoxicity and similar transfection efficiency in A549 and HepG2 lung cancer cells (Peng et 
al., 2011).  
Ishitsuka et al. (2011) developed a multifunctional envelope-type nano device (MEND), in 
which plasmid DNA is condensed using a polycation to form a core particle that is 
encapsulated in a lipid envelope, modified with the IRQ peptide (IRQRRRR) to enhance 
transgene expression in lungs. (Ishitsuka et al., 2011).  
Clinical applications of liposomes and nanoparticles for drug delivery to the respiratory 
tract are still in early stages. The key to future innovation may lie at the interface between 
biology and particle engineering. Improved understanding of biological processes 
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including particle clearance, cellular targeting, intracellular trafficking, and drug 
absorption are needed to better design formulations that deliver to the ‘‘target’’ with the 
optimal balance of pharmacodynamic, pharmacokinetic, and safety profiles. More 
specifically, continued advances are needed in the development of: (1) controlled release 
formulations; (2) formulations with improved regional targeting within the lungs (e.g., 
airway versus alveoli and vice versa); (3) formulations containing active targeting 
moieties; (4) formulation strategies for improving the systemic bioavailability of inhaled 
macromolecules; (5) formulation strategies for delivering macromolecules, including 
siRNA and DNA, into cells; and (6 ) formulations with improved dose consistency. It is 
likely that such innovation will require the development of novel excipients and particle 
engineering strategies. Future innovation must also take into account the changing 
marketplace and the diverse set of customers (patient, healthcare professional, heath 
authorities, payers, and politicians) who must be satisfied. The pharmacoeconomics of 
new delivery systems will be closely scrutinized, so it is imperative that cost factors 
should be taken into account. Otherwise, the new technology option may overshoot the 
evolving inhalation marketplace. 
4. Toxicity of nanoparticles to the lung 
Epidemiological studies have confirmed a positive correlation between levels of particulate 
pollution and increased morbidity and mortality rates among general populations (Gwinn & 
Vallyathan, 2006;  Stone et al., 2007).  
The adverse health effects seem to be dominated by pulmonary symptoms. For instance, 
many reports have addressed that occupational exposure of inhaled rigid nanoparticles 
(NPs) can lead to respiratory diseases such as pneumoconiosis (pulmonary fibrosis) and 
bronchitis (Byrne & Baugh, 2008; Lkhasuren et al., 2007). 
Increasing inhalation of ambient ultrafine particles has been linked with exacerbation of 
respiratory symptoms and mortality among COPD sufferers (Xia et al., 2009). It has also 
been documented that NPs can instigate oxidative stress and cellular toxicity in various 
types of cells (Huang et al., 2009).  
It was also reported that chronic exposure to NPs can potentially predispose humans to lung 
inflammation and increase the risk of COPD.  
A concentration range of NPs within the level found in ambience and in nanotechnology 
industries (Klaine et al., 2008) can promote mucin aggregation. 
The second safety aspect of deep lung deposition is the interaction of nanoparticles with the 
alveolar environment. The alveolar space is covered with a thin surfactant film. This film 
has important physiological functions e.g. to accelerate gas exchange and to lower the 
surface tension in the alveolar space. Compromising these functions by inhalable 
nanoparticles might cause life threatening consequences. Therefore, the compatibility of a 
delivery system with the alveolar environment must be considered (Azarmi et al., 2008). 
For these reasons vesicular nanocarriers, composed of lung surfactants and/or synthetic 
amphiphiles, provide an efficient delivery system for the treatment of pulmonary disorders 
due to their biocompatibility, biodegradability and non-toxic nature (Taylor & Newton, 
2004). 
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5. Chronic obstructive pulmonary disease (COPD) 
COPD is the fourth leading cause of death in the United States and Europe, with COPD 
mortality more than doubling in the last two decades (Mannino et al., 2002). COPD can be 
defined as a preventable and treatable disease state characterized by airflow limitation 
that is not fully reversible. The airflow limitation is usually progressive and is associated 
with an abnormal inflammatory response of the lungs to noxious particles or gases, 
primarily caused by cigarette smoking. Although COPD affects the lungs, it also produces 
significant systemic consequences (Celli & MacNee, 2004). It is interesting to point out 
how the definition of COPD has evolved including the systemic consequences of the 
disease. The natural history of the disease reveals numerous extrapulmonary 
manifestations and comorbidity factors that complicate the evolution of COPD, thereby 
altering the prognosis and quality of life of patients (Barnes & Celli, 2009; Agusti & 
Soriano, 2008). Many extrapulmonary effects of COPD have been described over the last 
two decades, including renal and hormonal abnormalities, muscle wasting (Remels et al., 
2007), osteoporosis, anemia and reduction in circulating bone marrow progenitors 
(Palange et al., 2006). Although these systemic manifestations have been described for 
years in COPD patients, it is still unclear whether they represent consequences of the 
pulmonary disorder, or whether COPD should be considered as a systemic disease. The 
importance of establishing the distinction between a respiratory disease with 
extrapulmonary manifestations and a systemic inflammatory state with multiple 
compromised organs is justified by different therapeutic options: in the first definition, 
therapy is primarily centred on the lungs, whereas in the second, therapy could aim at the 
systemic inflammatory state. Both submucosal gland hypertrophy and airway surface 
goblet cell metaplasia are prominent features of the chronic bronchitis that occurs in most 
COPD patients. While cough and chronic expectoration helps to remove excess mucus 
from the large airways, impaired mucociliary function in COPD causes ineffective mucus 
clearance from small airways (≤2 mm diameter) which are not well cleared by cough. Like 
asthma and CF, COPD is strongly associated with the accumulation of inflammatory 
mucous exudates in the lumens of small airways (Hogg et al., 2004). Accordingly, 
declining lung function, respiratory infections, hospital admission, and mortality are 
significantly associated with chronic expectoration. 
Among the numerous extrapulmonary effects of COPD, systemic inflammation has been 
widely studied and considered as an important key between the pulmonary disease and the 
related systemic manifestations. Many studies reported changes in various inflammatory 
cells and mediators, including neutrophils, lymphocytes, acute-phase reactants, and 
cytokines. Recently it was shown that systemic inflammation is present during COPD 
exacerbations and stable phases of the disease: increased numbers of leukocytes, levels of 
acute-phase response proteins (C-reactive protein and fibrinogen), cytokines such as 
interleukin (IL)-6, and tumor necrosis factor (TNF)- are present in the peripheral blood of 
COPD patients (Gan et al., 2004). Systemic inflammation has been implicated in the 
pathogenesis of the majority of COPD systemic effects, including weight loss (Wouters, 
2002), skeletal muscle dysfunction, cardiovascular diseases (Sin & Man, 2003), and 
osteoporosis, although it is still controversial whether this so called low-grade systemic 
inflammation represents the consequence of pulmonary inflammation into the systemic 
vascular bed (Agustı` et al. 2003), or whether it is a systemic inflammation. Although 
inflammation is certainly one of the major features of COPD, we still need to understand 
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whether the local inflammation is sufficient to induce systemic effects, or whether a second 
pathogenetic event is required (Evans & Koo, 2009; Huertas & Palange 2011). 
Over the years it was evidenced that mucus hypersecretion is an important manifestation 
of COPD. In the classical phenotype of chronic bronchitis, mucus hypersecretion is the 
key presenting symptom that appears  independent of airflow obstruction. A more recent 
work demonstrated that obstruction of the small airways by inflammatory exudates 
containing mucus is predictive of early death after volume reduction surgery in patients 
with advanced COPD (Hogg et al., 2007). It was suggested that such occlusion enhanced 
the probability of infection in the lower respiratory tract. In addition, several 
epidemiological studies showed an association between mucus hypersecretion and 
outcomes in patients with COPD. Mucus hypersecretion is not an innocent disorder. 
However, despite these observations, until now few studies have focused on the effects of 
mucolytic drugs in patients with COPD, even though some of these mucolytic drugs also 
appear to have antioxidant properties (Dekhuijzen, 2004;  Rahman et al., 1997; Rahman & 
Kilty 2006; Decramer & Janssens, 2010).  
Histopathological findings from surgical specimens clearly show that increased goblet cell 
numbers and increased MUC5AC and MUC5B production and secretion are found in the 
lumen of small airways in COPD patients (Caramori et al., 2004). These findings are 
inversely associated with pre-surgical Forced Expiratory Volume in the 1st second (FEV1). 
Thus, patients with higher FEV1 have less goblet cell metaplasia than patients with lower 
FEV1, suggesting that the presence of mucin-producing cells in the airways is related to 
increased airflow obstruction. The presence of a prominent goblet cell phenotype also 
negatively correlates with FEV1 improvement following lung volume reduction surgery 
(Kim et al., 2005). Collectively, these results show that mucus secretion may be significant 
enough to result in physiologically and clinically measurable mechanical obstruction of 
small airways, and it may significantly impact disease pathogenesis and prognosis. The 
main cause of COPD in humans is cigarette smoking. In mice, chronic cigarette smoke 
exposure causes strain dependent mucous metaplasia. Cigarette smoke itself has also been 
shown to promote mucin synthesis directly in vitro by activation of the EGFR cascade (Shao 
et al., 2004). Inhalation, of one of the many potential toxicants present in cigarette smoke, 
acrolein (acrylic aldehyde), induces mucous metaplasia and MUC5AC production in 
animals. Acrolein also induces MUC5AC production in human airway epithelial cell lines, 
and it is found at significantly elevated levels in the induced sputum and exhaled breath 
condensates of COPD patients, (Deshmukh et al., 2008). 
It has been suggested that mucus can also serve as a suitable medium for adherence and 
growth of some bacterial pathogens, such as non-typeable H. influenzae. Gram positive and 
gram negative bacteria products up-regulate MUC5AC and MUC2 gene expression and 
mucin secretion in human respiratory epithelial cell lines in vitro, and the same effect can be 
seen in some animal models in vivo. Viral infections are also closely associated with COPD 
exacerbations in humans (Wedzicha & Donaldson, 2003; Beckham et al., 2005). Surgical 
specimens from smokers with COPD show increased goblet cell numbers in the epithelium 
of peripheral airways compared to non-smokers. This is accompanied by increased 
macrophages and CD8 positive T-lymphocytes, both of which are indicative of viral. Roles 
for IL-6 and virus-induced mucin overproduction have been suggested. In vivo, IL-6 
production is enhanced during the early phase of bacterial or viral-induced inflammation. 
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Accordingly, IL-6 levels are increased in COPD patients (Bucchioni et al., 2003), and during 
experimental respiratory viral infections in humans and mice (Decramer & Janssens, 2010). 
5.1 Mucus rheological properties 
Mucus rheology plays a critical role in maintaining respiratory health. Mucins are large, 
highly glycosylated proteins. The polyanionic nature of mucin stems primarily from sialic 
acid, sulfate, and carboxyl groups present in these linked oligosaccharides. Beside physical 
entanglement, cationic calcium ions can act as crosslinkers that condense the mucin matrices 
inside mucin granules before exocytosis. Upon release, phase transition mainly driven by 
the Donnan effect triggers the massive decondensation of mucin networks. Hydrogen 
bonding, hydrophilic and hydrophobic interactions have also been proposed to contribute 
to the gel properties of mucin The gel characteristics and rheological properties of mucin are 
critical for the maintainance the integrity of epithelia by trapping bacteria and viruses and 
for mucociliary clearance (Bansil & Stanley, 1995; Verdugo, 1990). 
Mucus is mainly composed of large and heavily glycosylated glycoproteins called mucins. 
The gel-forming mucins rapidly hydrate after exocytosis and, due to their tangle network 
properties, anneal with other mucins to form a protective barrier at the airway-surface 
liquid layer. The mucin gel layer lines the epithelial surface of various organs such as the 
vaginal tract, eyes, gastric wall and pulmonary lumen. Mucus in the airway of lungs serves 
as an innate immune defense against inhaled particulates, bacteria and viruses. Maintenance 
of the airway protection mechanism stems from the delicate balance between normal mucus 
production, transport and clearance. The mucin polymer network of mucus has a 
characteristic tangled topology. Since the rheological properties of mucus are governed 
mainly by the tangle density of mucin polymers, which decreases with the square of the 
volume of the mucin matrix, the mucin network hydration (degree of swelling) is the most 
critical factor in determining the rheological properties of mucus. The diffusivity of mucin 
matrices, which is closely related to mucin viscosity, can be calculated from polymer 
swelling kinetics. Based on the polymer network theory, polymer diffusivity is inversely 
proportional to its viscosity (Lodge, 1999). Thus, lower rate of mucin diffusivity is associated 
with higher viscosity, less dispersed and less transportable mucins that appear to 
characterize the clinical symptoms of thick mucus accumulation and obstruction commonly 
found in asthma, COPD and CF 44. (Rogers, 2007). 
The clinical manifestation of major respiratory diseases (Rogers & Barnes, 2006; Quinton, 
2008) are related to thick mucus. 
The relationship between mucin dehydration and defective mucus clearance has been well 
established (Mall et al., 2004). As a result, the poorly hydrated, highly viscous and less 
transportable mucus appears to accumulate within airway passages (Randell et al., 2006). 
Obstruction of airway lumen with viscous mucus is usually accompanied by chronic 
bacterial infection, inflammation and impaired mucociliary transport. 
6. Case studies 
Although the use of liposomes for aerosol formulations is certainly encouraging, liposome 
nebulization still presents some problems, i.e. storage stability (mainly related to oxidation 
processes) and leakage of encapsulated drugs. In addition, it should be also considered that 
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synthetic phospholipids are usually expensive and, on the other side, natural phospholipids 
show a variable degree of purity (Desai & Finlay, 2002). 
An alternative approach to the liposomal approach is the use of liposome-like vesicles made 
up of non-ionic surfactants, the so-called niosomes. These carriers were proposed for both 
topical (Carafa et al., 2000; Carafa et al., 2004; Paolino et al., 2007; Paolino et al., 2008) and 
systemic administration (Cosco et al., 2009). 
Here we report the evaluation of the possible advantages of a new type of non-phospholipid 
vesicle system for pulmonary drug delivery that can lead to an improved mucus 
permeation. Vesicles consisting of one or more surfactant bilayers enclosing aqueous spaces 
(non ionic surfactant vesicles NSVs), are of particular interest because they offer several 
advantages with regard to chemical stability, lower cost and availability of materials 
compared to conventional liposomes 
In the formulation of inhaled drugs for the treatment of asthma and COPD, considerable 
attention has been devoted to new aerosol morphologies which can either enhance the local 
effect and/or increase the penetration through the mucus, secreted in bronchial 
inflammatory diseases. In diseases characterized by bronchial hypersecretion, lipophilic 
substances, such as corticosteroids, can be remarkably impeded in reaching their receptors, 
which are localized within the cytoplasm of bronchial epithelial cells. 
In particular, alveolar macrophages are important target cells for the therapeutic action of 
glucocorticoids, because these cells are the major source of both proinflammatory and 
antiinflammatory cytokines. The action of glucocorticoids is mediated by an intracellular 
receptor belonging to the steroid thyroid/retinoic acid receptor superfamily (Oakley et al., 
1999). 
With the purpose of carrying out research leading to an innovative formulation for lung 
delivery capable of permeating the mucous layer and of an efficient delivery to alveolar 
macrophages, beclomethasone dipropionate (BDP), clinically used for the treatment of 
asthma and COPD, was entrapped in non-phospholipid vesicles.  
BDP, as a reference model drug, was encapsulated in vesicular structures obtained with 
polysorbate 20. The aim of the study was to evaluate in vitro the effectiveness of such 
delivery system that should enhance permeation through mucosal barriers because of the 
presence of vesicles formed with a remarkably hydrophilic non-ionic surfactant usually 
considered as unsuitable for the formation of vesicular structures because of its high HLB 
value (HLB 16.7) (Santucci et al., 1996). 
The intracellular availability of BDP and the safety of the delivery system are the two main 
issues to be addressed to propose these innovative non-ionic surfactant vesicles as carriers 
for the pulmonary delivery of this drug to be effectively used for the treatment of 
pulmonary inflammatory diseases. Therefore, the aim of this investigation was the 
evaluation of the interaction between our innovative non-ionic surfactant vesicles and 
human lung fibroblast (HLF) cells, the carrier tolerability, the vesicle localization within the 
cells and the amount of BDP actually internalized by the cells. 
Unilamellar vesicles were obtained from a non-ionic surfactant/BDP aqueous dispersion 
(Hepes pH 7.4) by means of the “film” method as previously reported (Santucci et al., 1996), 
according to the compositions reported in Table 1. 
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Sample Polysorbate 20 Cholesterol BDP 
1 1.84 0.58 0.5 
2 1.84 0.58 1.0 
3 1.84 0.58 3.0 
4 1.84 0.58 5.0 
5 3.68 1.16 0.5 
6 3.68 1.16 1.0 
7 3.68 1.16 3.0 
8 3.68 1.16 5.0 
Table 1. Sample composition (expressed as % w/v) 
All compositions are able to form nanovesicles with different size and zeta potential (ζ-
potential) according to the various formulations (Table 1). The size and the polydispersity 
index (PDI) obtained by dynamic light scattering measurements indicated those 
formulations with the smallest size and the most homogeneous nanovesicles population that 
can be obtained: samples 2 and 8, chosen to perform further experiments. 
Size measurement experiments indicate that BDP-loaded vesicles are slightly larger than 
empty ones as reported in Table 2 for samples 2 and 8 of Table 1, there is an increase in 
diameter between 10 and 20%, and this expected effect can be related to drug partition 
between the bilayer and the aqueous core of the vesicles. Accordingly, the presence of BDP 
in the formulation may affects the ζ-potential values; as it is possible to observe from Table 
2, the corresponding samples 2 and 8 show a significant decrease in ζ-potential that 
approaches the value obtained with BDP alone. This effect can be related to the chemical 
steroidic structure of the drug that is somehow similar to that of cholesterol, thus allowing it 
to fit well within the vesicular structure. 
 
Sample Dimensions (nm) ζ -potential (mV) 
2 163±0.03 -32±0.2 
8 174±0.02 -34±0.3 
Empty vesicles 146±0.05 -40±0.2 
BDP solution 0.05% w/v = -30±0.1 
Table 2. Vesicle dimensions (nm) and ζ- potential (mV) of analyzed samples (n=3; ±SD) 
Furthermore, it should be pointed out that electron microscopy carried out on numerous 
samples (10) indicated that nebulization does not influence drug-loaded vesicle dimensions 
(Figure 5A and B). 
Analyzed samples showed a good stability in terms of possible changes in vesicle 
dimensions after aggregation. 
Size measurement experiments indicated that after 1 month at 25 °C, no appreciable vesicle 
dimension variations could be detected. 
The best entrapment efficiency (e.e.) was obtained for sample 8 and the calculated drug e.e. 
indicated that only about 20% of the overall amount of BDP is actually enclosed within the 
vesicles. This result is in agreement with the data reported by previous authors (Montenegro  
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Fig. 5. Trasmission electron micrographs of BDP-loaded vesicles after freeze-fracture, before 
(A) and after (B) nebulization. The scale bar represents 0.5 m. 
et al., 1996; Darwis et al., 2001). For this reason, for permeation and nebulization 
experiments the formulation corresponding to sample 8 of Table 1 was used. 
The possibility to use the novel vesicular dispersion in a conventional jet nebulizer, widely 
used in clinical applications, was also evaluated. For this purpose, samples were 
characterized also by means of rheological measurements and the aerodynamic diameter 
was determined (Table 3) as well as the nebulizer mass output (Figure 6) after completion of 
nebulization. Evaluation of Mass Median Aerodynamic Diameter (2.0±0.2 µm) and of 
geometric standard deviation (GSD) were also carried out; the GSD value (1.5) demonstrates 
the polydisperse nature of the distribution of the aerosolized droplets that, on the other side, 
contained a monodisperse vesicular system. 
 
Aerodynamic diameter Percentage
<10 100 
<5 99.5 
<2 65 
Table 3. Percentage of particles with aerodynamic diameter   <10, < 5, <2 µm, containing 
non-ionic surfactant vesicles, delivered by a jet nebulizer 
 
 
Fig. 6. Deposition of vesicle-encapsulated BDP (BDP/ves) on filters upon nebulization, 
compared to a BDP/surfactant solution and to a BDP commercial product (n=3, ±SD). 
A B 
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Furthermore, in all conditions of nebulization (TurboBoy nebulizer and Clenny nebulizer), 
the dispersion BDP/vesicles releases a greater amount of drug, dosed by HPLC, with 
respect to commercial formulations. 
An important aspect to be taken into account for an actual application of these non-ionic 
surfactant vesicles as possible carriers to be aerosolized for the pulmonary delivery of drugs 
is their colloidal and storage stability. 
In fact, the occurrence of aggregation phenomena can lead to a significant worsening of the 
biopharmaceutical features of nanosized colloidal suspensions, such as NSVs. Therefore, the 
colloidal stability of BDP-loaded NSVs was evaluated using the Turbiscan Lab® Expert 
(Celia et al., 2009) i.e. the optical transmission and the photon backscattering profiles of 
various samples were recorded. Any variation of the vesicle volume fraction (migration) or 
mean size (coalescence) triggers the variation of backscattering (BS) and transmission (T) 
signals, which are graphically reported as positive (backscattering/transmission increase) or 
negative (backscattering/transmission decrease) peaks. It can be assumed that no variation 
of particle size occurs when the ΔBS and ΔT profiles are within an interval of ±2% while 
variations greater than 10% either as a positive or a negative value are representative of an 
instable formulation. 
Two different BDP concentrations, i.e. 50 mg/ml (sample BDP-50) and 0.4 mg/ml (BDP-0.4), 
were used in this stability investigations. The first concentration led to the maximum 
possible amount of drug entrapment within the NSVs, while the second concentration led to 
an amount of entrapped drug similar to that actually present in the most common 
commercial products. 
The ΔBS and ΔT profiles of BDP -loaded and unloaded non-ionic surfactant vesicles are 
shown in Figure 7. 
 
 
 1  2             3               4         5 
Fig. 7. Transmission and backscattering profiles of niosomes by using Turbiscan Lab® 
Expert. The image represents the analysis of different formulations: (1) unpurified BDP-50-
niosomes; (2) purified BDP-50-niosomes; (3) unpurified BDP-0.4-niosomes; (4) purified BDP-
0.4-niosomes; (5) unloaded niosomes. Data are reported as a function of time (0–3 h) and 
sample height (from 2 to 20 mm). 
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The transmission signal remained close to the base line value and ΔT profiles close to 0% 
were observed for all the investigated NSV formulations during the entire time of analysis. 
Therefore, NSVs suspensions maintained a constant opalescent aspect along the height of 
various samples. At the same time, positive or negative variations of the backscattering 
profiles of the different formulations (Figure 7) were not correlated to destabilization 
processes under the sample height of 2 mm and over that of 20 mm, the values having been 
determined by enclosed air in the bottom and/or on the top of the cylindrical glass tube, 
respectively. Different NSVs formulations showed that backscattering emerged as the 
prevalent signal in the different measurements (Figure 7). ΔBS signals are close to ~1% 
during the time of analysis for the entire height of the samples of both purified BDP-loaded 
and unloaded non-ionic surfactant vesicles (Figure 7 panels B, D and F). It was interesting to 
observe that the different amounts of the entrapped drug do not influence the colloidal 
stability of non-ionic surfactant vesicles both in terms of vesicle migration and coalescence. 
Different stability behaviors, as shown by ΔBS profiles (Figure 7 panels A and C), were 
observed in the case of not purified BDP loaded non-ionic surfactant vesicles (i.e. before gel 
exclusion chromatography). 
In particular, vesicles prepared in the presence of the highest drug concentration (50 
mg/ml) showed a high colloidal instability just after the beginning of the analysis. A 
moderate stability (ΔBS profile within the 10% during the 3 h of analysis) was observed for 
unpurified non-ionic surfactant vesicles prepared in the presence of 0.4 mg/ml of the drug, 
while an elevated stability (equal to purified formulations) was observed for unpurified 
unloaded vesicles (Figure 7 panel E). These findings can be due to the presence of high 
amount of free drug, that with time leads to the formation of aggregates. Therefore, the 
purification procedure is essential to achieve a stable vesicular colloidal carrier for the 
delivery of BDP. The stability findings by Turbiscan Lab® Expert measurement were also 
supported by light scattering size analysis during a storage period of 3 months, which 
showed no appreciable vesicle size variation for purified BDP-loaded non-ionic surfactant 
vesicles. 
According to the aim of this research, the capability of ensuring a better penetration through 
the mucus layer of vesicular formulation was tested. 
In Figure 8, the permeation rate of BDP from the vesicular dispersion is reported and 
compared with that obtained using a BDP/polysorbate 20 (at the same concentration used 
for vesicle preparation) suspension as well as with that of the commercial preparation. The 
vesicular formulation (BDP-0.4) was used in its unpurified form, thus with the drug 
partitioned inside and outside the vesicular structure. 
This situation allows an appropriate comparison with the other preparations used in 
permeation experiments: since both micellar surfactant solutions and the commercial one 
contained free BDP and BDP included within aggregated structures (micelles). As it can be 
observed, the presence of NSVs in the formulation remarkably increases the permeation rate 
through the model mucosal barrier with respect to the other tested preparation thus 
indicating that the novel BDP formulation can be proposed for a better targeting of 
corticosteroids in the treatment of COPD. 
An important aspect to evaluate an innovative drug delivery system is its safety. This aspect 
is much more relevant in the case of pulmonary delivery, since several side effects may  
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Fig. 8. Comparison of the permeation patterns through a gel-like mucin solution (0.1%w/v), 
expressed as percentage of permeated drug as a function of time (n=3, ±SD) 
(BDP/surfactant  ▲BDP/commercial product  BDP/vesicles). 
result from an unsafe material, i.e. fibrosis, pulmonary oedema, inflammation, as reported 
in section 4. 
Safety of empty non-ionic surfactant vesicles was evaluated in vitro on HLF cells by using 
the trypan blue dye exclusion assay (cell mortality) and MTT viability test. Purified and 
unpurified empty NSVs were assayed in vitro at different surfactant concentrations (from 
0.01 to 10 μM) and incubation-times (24, 48 and 72 h). 
Purified non-ionic surfactant vesicles did not show a significant cytotoxic activity on HLF 
cells at all incubation times for concentrations ranging from 0.01 to 1 μM, i.e. the mortality 
values ranged from 1.2 to 5.81%, respectively. Only at the highest investigated concentration 
(10 μM) and after 48 h of incubation a slight cytotoxic effect was observed (mortality value 
of 16%). 
It is interesting to point out that unpurified vesicles showed a significant (P<0.001) increase 
of cytotoxicity with respect to purified vesicles at all the investigated conditions (exposition 
times and surfactant concentrations). In this sense it was also observed that the increase of 
the cytotoxic effect was dependent on surfactant concentration but not on the exposition 
time. This finding was due to the fact that the cytotoxic action of unpurified NSVs was 
determined by the presence of the free molecules of surfactants, which were able to exert 
immediately their cytotoxic action during the incubation period by noticeably perturbing 
the cellular membranes (Dimitrijevic et al., 2000; Lin et al., 2007) and hence causing the 
cellular death. This hypothesis was strongly supported by the evidence that HLF cells 
treated with the free surfactants showed a greater (P<0.001) cytotoxic insult than those 
treated with unpurified non-ionic surfactant vesicles. Therefore, the assembling of surfactant 
into non-ionic surfactant vesicles determined a drastic reduction of cytotoxicity, due to a 
concomitant reduction of the free surfactant molecules in solution and/or surfactant 
micelles, which are able to alter the cellular permeability and homeostasis. 
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Another important feature of an innovative drug delivery system is to increase the amount 
of active compound in the target district, thus improving the therapeutic effect of the drug. 
Therefore, to evaluate the delivery ability and the mechanisms of interaction of fluorescein-
labelled non-ionic surfactant vesicles with HLF cells, CLSM experiments were carried out.  
Figure 9 shows how the fluorescein-labelled vesicles interacted with HLF cells at different 
incubation times. A green fluorescence distribution was observed in the cells just after 1 h 
incubation. After 3 h incubation the fluorescence of the cellular membrane and the 
cytoplasm became more intense and increased slightly up to 24 h of incubation. These 
findings prompted us to suppose that the main mechanism involved in the NSVs/cell 
interaction was the endocytosis of the carrier (Di Marzio et al., 2008), which enabled a rapid 
internalization in the cytoplasm. It is worthy of note that at all incubation times the 
localization of fluorescence was in the cytoplasm compartment and these results represent 
an important aspect because the glucocorticoid receptor is localized in the cytoplasm. 
No fluorescence was detected in the untreated HLF cell line (control) and hence there was 
no interfering auto-fluorescence phenomenon (Figure 9 panel 6).  
   1 h  3 h  6 h 
 
   12 h  24 h              control 
Fig. 9. CLSM micrographs of the interaction of fluoresceine-labelled NSVs with primary 
HLF cells as a function of the incubation times,. The reflectance CLSM micrographs of 
untreated cells were used as controls and no significant cellular fluorescence was observed  
As a consequence, the improved interaction of NSVs with primary HLF cells should lead to 
a greater intracellular delivery of the entrapped drug. 
For this reason the intracellular uptake of BDP prompted by the various formulations was 
investigated as a function of time (Figure 10). 
Considering that surfactant molecules and unloaded non-ionic surfactant vesicles may act as 
drug cellular penetration enhancers and to evaluate the effective role of the vesicles in the 
promotion of the intracellular uptake of BDP, a mixture surfactant/BDP and a mixture 
empty vesicles/BDP was also assayed. As reported in Figure 10, BDP loaded non-ionic 
surfactant vesicles (BDP-0.4) showed a significant improvement of the intracellular uptake 
of the drug with respect to a mixture surfactant/BDP, a mixture empty non-ionic surfactant  
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Fig. 10. HLF intracellular uptake (I.U. at 37 °C) of beclomethasone dipropionate (expressed 
as percentage of the applied dose) as a function of time by different formulations: BDP 
loaded NSVs (BDP-0.4), ●; surfactant/BDP mixture, ▲; empty non-ionic surfactant 
vesicle/BDP mixture, ■; free drug, ♦.  
vesicle/BDP and a free drug solution. This result was correlated to the ability of NSVs to 
easily penetrate across cell membranes of primary HLF cells (in full agreement with CSLM 
experiments), thus achieving a noticeable cytoplasm accumulation of BDP. These results 
clearly evidenced that the improvement of the drug intracellular uptake was mainly 
mediated by the vesicular carrier and no positive  influence was exerted by the surfactant 
molecules and/or empty vesicles, i.e. the drug has to be entrapped within the carrier. In fact, 
the mixtures surfactant/drug and empty vesicle/drug showed only a slight improvement of 
the intracellular uptake of BDP. The profiles of BDP intracellular uptake as a function of 
time showed (Figure 10) a Tmax (time at which the maximum drug concentration was 
reached) value of 1 h followed by a gradual reduction of the intracellular drug accumulation 
up to 6 h in the case of the drug-loaded non-ionic surfactant vesicles. On the other side, all 
other tested formulations showed Tmax values of 30 min. 
The rapid internalization of BDP formulated in niosomes was not considered as a critical 
parameter.  
The evidence of the improved intracellular entrance of NSVs and the noticeable increase of 
the intracellular uptake of BDP mediated by the vesicular carrier should match an improved 
pharmacological activity of the delivered drug. For this reason the anti-inflammatory 
activity of BDP-loaded non-ionic surfactant vesicles was evaluated in comparison with the 
free drug, as the capacity to inhibit the secretion of NGF. 
NGF is an important inflammatory mediator, which contributes to the development of 
airway hyper-responsiveness (de Vries et al., 1999). The NGF production is stimulated by 
the presence of pro-inflammatory cytokines and asthma-associated cytokines, i.e. IL-1β, and 
I.U. (%) 
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inhibited by anti-inflammatory glucocorticoids. Therefore, the in vitro determination of the 
levels of NGF secreted by HLF cells is a direct evidence of the pro- or anti-inflammatory 
effect of a substance.  
As shown in Figure 11, the stimulation of HLF cells with IL-1β led to an over-secretion of 
NGF up to 210% of basal values (control). The treatment with the free BDP (1 μM) 
significantly reduced both the constitutive and the IL-1β-stimulated secretion of NGF by 
18.7% and 61.23%, respectively. BDP-loaded non-ionic surfactant vesicles (BDP-0.4) were 
much more effective than the free drug, i.e. a reduction of 68% and 85% with respect to the 
constitutive and IL-1β-stimulated NGF secretion were respectively observed. These findings 
are in agreement with both CLSM and intracellular uptake experiments.  
 
Fig. 11. Anti-inflammatory activity of various formulations containing  BDP (1 μM) evaluated 
as inhibition of NGF secretion in primary HLF cells treated with IL-1β (as pro-inflammatory 
stimulating agent). Control was untreated HLF cells, which secrete the basal level of NGF.  
The use of NSV formulations was investigated not only to increase intracellular uptake of 
BDP in HLF cells and to improve diffusion through mucus layer but also to design an 
innovative system able to increase therapeutic efficacy of BDP in pulmonary diseases thus 
reducing the dosage and potential side effects of this drug. 
7. Conclusions 
Despite the many promising proof - of - concepts of various delivery technologies, there is 
still a long way ahead that must be covered. This means there are still many challenges that 
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are being faced, which, in turn, mean there are still many chances for the academic and 
industrial scientist to make a decisive impact.  
Further research efforts are needed to ensure the safety of long-term in vivo applications. 
There is an urgent requirement for cautiously designed toxicology and toxicokinetic studies 
for each nanocarrier type; the protocols should be customized for an appropriate clinical 
use. Furthermore, it should be pointed out that scale up from laboratory to industry is still 
poorly investigated in this specific area, despite its obvious importance in the ultimate goal  
of the development a product that can reach the market  and actually give benefits to the 
patients. 
In spite of the above reported difficulties and challenges; hopefully, within a few years, the 
safety and large - scale production at affordable costs of the delivery technologies described 
in this book will be a dream that will become true. 
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